REGULATORY

Chuikyo OKs NHI Price Listing of Anti-HIV Drug Genvoya

June 23, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The health ministry’s Central Social Insurance Medical Council (Chuikyo) on June 22 approved the expedited NHI price listing of Japan Tobacco’s anti-HIV drug Genvoya (elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide (TAF)). The drug will be listed on June…

To read the full story

Anti-HIV Drug Genvoya Approved in Japan
June 20, 2016

REGULATORY

Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
Japan, Spain Move to Deepen Pharmaceutical Regulatory Cooperation
December 23, 2025
Japan Drops Transitional Plan for PCV20 Routine Shot in Elderly
December 23, 2025
Tecartus Now in Line for Orphan Status with Japan Panel Nod
December 23, 2025
LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…